Advertisement
Mr. Suen has 18 years of experience in the investment industry both as aninvestor and as an operator of companies. His career began at Bear Stearnsand Co. in 1988 as the youngest hire in the firm's history. During hisfive-year tenure, he worked in multiple disciplines, including mergerarbitrage, trading, sales, and M&A. Having been exposed to different aspectsof capital markets, he identified a niche for trading and in 1993 founded andmanaged Axis Trading Corp. Axis was a pioneer in online trading and executionthat is standard practice today. In January 1996, a division of Softbankacquired Axis, reaping a significant return for investors.
Advertisement
From 1997 to 2002, Mr. Suen was a principal in Elevation Capital, aventure capital fund at which he was responsible for identifying technologyand biotechnology investments, as well as advising management of investeecompanies on strategic direction and capital markets activities.
In 2002, Mr. Suen assumed the role of interim CEO of Muse Communications,one of Elevation's portfolio companies. He led Muse through a global productlaunch and structured a strategic partnership with Fujitsu to integrate Museinto Fujitsu's @Nifty portal.
In early 2003, at the invitation of Muse Communications' angel investors,Mr. Suen relocated to Hong Kong and joined IRG, Limited/IRG TMT Asia Fund.IRG invests in and advises Pan-Asia based technology and biotechnologycompanies (listed and private) on strategic partnerships, M&A, and capitalmarkets activities. IRG TMT Asia Fund is an investor in Sinobiomed and Brentjoined the Company in order to assist in the next phase of growth.
"As Director of Strategic Development, I will actively seek investment inSinobiomed from both strategic and financial investors, look for opportunisticM&A possibilities and position the Company to become a world class lifescience company," said Suen.
Banyun Yang, Sinobiomed CEO, said: "We welcome Mr. Suen in an officialcapacity as Director of Strategic Development. He's been working with us inan unofficial capacity for several months and is also an investor in theCompany thru IRG. His activities on our behalf have included the introductionof the Company to Lionel Choong, our new incoming CFO. We anticipate a numberof relationships being forged on the funding and strategic partnership side inthe near future and look forward with enthusiasm to Mr. Suen's involvement."
ABOUT SINOBIOMED INC.
Sinobiomed Inc. is a leading Chinese developer of genetically engineeredrecombinant protein drugs and vaccines. Based in Shanghai, Sinobiomedcurrently has 10 products approved or in development: three on the market,four in clinical trials and three in research and development. The Company'sproducts respond to a wide range of diseases and conditions, including:malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabeticulcers and burns, and blood cell regeneration.http://www.sinobiomed.com
FORWARD LOOKING STATEMENTS This news release may include "forward-lookingstatements" regarding Sinobiomed, and its subsidiaries, business and projectplans. Such forward looking statements are within the meaning of Section 27Aof the Securities Act of 1933, as amended, and section 21E of the UnitedStates Securities and Exchange Act of 1934, as amended, and are intended to becovered by the safe harbor created by such sections. Where Sinobiomedexpresses or implies an expectation or belief as to future events or results,such expectation or belief is believed to have a reasonable basis. However,forward-looking statements are subject to risks, uncertainties and otherfactors, which could cause actual results to differ m
